Sarah Vreugde

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9440986/publications.pdf

Version: 2024-02-01

133	4,007	117453	149479
papers	citations	34 h-index	56 g-index

136	136	136	4515
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Investigation of Kappa Carrageenan's mucoâ€adhesive, antibacterial, and antiâ€biofilm properties. International Forum of Allergy and Rhinology, 2022, 12, 302-305.	1.5	2
2	Silver nanoparticles as a bioadjuvant of antibiotics against biofilm-mediated infections with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis patients. Pathology, 2022, 54, 453-459.	0.3	15
3	APTC-EC-2A: A Lytic Phage Targeting Multidrug Resistant E. coli Planktonic Cells and Biofilms. Microorganisms, 2022, 10, 102.	1.6	6
4	In vitro and in vivo evaluation of probiotic properties of Corynebacterium accolens isolated from the human nasal cavity. Microbiological Research, 2022, 255, 126927.	2.5	5
5	Effect of breathing profiles on nebuliser drug delivery targeting the paranasal sinuses in a post-operative nasal cavity. Journal of Aerosol Science, 2022, 161, 105913.	1.8	8
6	Prophage: a crucial catalyst in infectious disease modulation. Lancet Microbe, The, 2022, 3, e162-e163.	3.4	10
7	In vitro safety and antiâ€bacterial efficacy assessment of acriflavine. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1917-1920.	2.7	0
8	Efficacy and Safety of Novel Beta-Chitin Patches as Haemostat in Rat Vascular and Neurosurgical Model. Frontiers in Surgery, 2022, 9, 830364.	0.6	1
9	Chitogel following endoscopic sinus surgery promotes a healthy microbiome and reduces postoperative infections. International Forum of Allergy and Rhinology, 2022, 12, 1362-1376.	1.5	5
10	Genomic characterization of three bacteriophages targeting multidrug resistant clinical isolates of Escherichia, Klebsiella and Salmonella. Archives of Microbiology, 2022, 204, 334.	1.0	6
11	APTC-C-SA01: A Novel Bacteriophage Cocktail Targeting Staphylococcus aureus and MRSA Biofilms. International Journal of Molecular Sciences, 2022, 23, 6116.	1.8	9
12	Chronic Rhinosinusitis, S. aureus Biofilm and Secreted Products, Inflammatory Responses, and Disease Severity. Biomedicines, 2022, 10, 1362.	1.4	11
13	Tertiary Lymphoid Organs: A Primer for Otolaryngologists. Laryngoscope, 2021, 131, 1697-1703.	1.1	1
14	Proteomic analysis of nasal mucus samples of healthy patients and patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2021, 147, 168-178.	1.5	25
15	Tween 80 and its derivative oleic acid promote the growth of Corynebacterium accolens and inhibit Staphylococcus aureus clinical isolates. International Forum of Allergy and Rhinology, 2021, 11, 810-813.	1.5	4
16	Role of intracellular zinc in molecular and cellular function in allergic inflammatory diseases. Allergology International, 2021, 70, 190-200.	1.4	22
17	Prevention of adhesions post-abdominal surgery: Assessing the safety and efficacy of Chitogel with Deferiprone in a rat model. PLoS ONE, 2021, 16, e0244503.	1.1	4
18	Metallothionein-3 is a clinical biomarker for tissue zinc levels in nasal mucosa. Auris Nasus Larynx, 2021, 48, 890-897.	0.5	3

#	Article	IF	Citations
19	Optimising Aerosol Delivery for Maxillary Sinus Deposition in a Post-FESS Sinonasal Cavities. Aerosol and Air Quality Research, 2021, 21, 210098.	0.9	3
20	Corynebacterium accolens Has Antimicrobial Activity against Staphylococcus aureus and Methicillin-Resistant S. aureus Pathogens Isolated from the Sinonasal Niche of Chronic Rhinosinusitis Patients. Pathogens, 2021, 10, 207.	1.2	31
21	Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells. Frontiers in Cellular and Infection Microbiology, 2021, 11, 655666.	1.8	11
22	Overcoming bacteriophage insensitivity in Staphylococcus aureus using clindamycin and azithromycinat subinhibitory concentrations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3446-3458.	2.7	9
23	Association between mucosal barrier disruption by Pseudomonas aeruginosa exoproteins and asthma in patients with chronic rhinosinusitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3459-3469.	2.7	19
24	Colloidal silver combating pathogenic Pseudomonas aeruginosa and MRSA in chronic rhinosinusitis. Colloids and Surfaces B: Biointerfaces, 2021, 202, 111675.	2.5	17
25	Cytokine-Induced Modulation of SARS-CoV2 Receptor Expression in Primary Human Nasal Epithelial Cells. Pathogens, 2021, 10, 848.	1.2	2
26	Optimal primer selection for sinus microbiome profiling: A comparative analysis of the V1â€V3 and V3â€4 16S target regions. International Forum of Allergy and Rhinology, 2021, 11, 1698-1702.	1.5	2
27	3D bioprinting of a cell-laden antibacterial polysaccharide hydrogel composite. Carbohydrate Polymers, 2021, 264, 117989.	5.1	48
28	Der p 1 Disrupts the Epithelial Barrier and Induces IL-6 Production in Patients With House Dust Mite Allergic Rhinitis. Frontiers in Allergy, 2021, 2, 692049.	1.2	6
29	The effect of chemical and structural modifiers on the haemostatic process and cytotoxicity of the beta-chitin patch. Scientific Reports, 2021, 11, 18577.	1.6	0
30	Preclinical Development of a Bacteriophage Cocktail for Treating Multidrug Resistant Pseudomonas aeruginosa Infections. Microorganisms, 2021, 9, 2001.	1.6	9
31	Converging 2D Nanomaterials and 3D Bioprinting Technology: Stateâ€ofâ€theâ€Art, Challenges, and Potential Outlook in Biomedical Applications. Advanced Healthcare Materials, 2021, 10, e2101439.	3.9	9
32	Acoustic drug delivery to the maxillary sinus. International Journal of Pharmaceutics, 2021, 606, 120927.	2.6	16
33	Comparative antibacterial activity of 2D materials coated on porous-titania. Journal of Materials Chemistry B, 2021, 9, 6412-6424.	2.9	10
34	Green synthesized colloidal silver is devoid of toxic effects on primary human nasal epithelial cells in vitro. Food and Chemical Toxicology, 2021, 157, 112606.	1.8	5
35	Trimellitic anhydride facilitates transepithelial permeability disrupting tight junctions in sinonasal epithelial cells. Toxicology Letters, 2021, 353, 27-33.	0.4	4
36	The potential of chitosan-based haemostats for use in neurosurgical setting â€“ Literature review. Journal of Clinical Neuroscience, 2021, 94, 128-134.	0.8	7

#	Article	IF	Citations
37	TLR Signals in Epithelial Cells in the Nasal Cavity and Paranasal Sinuses. Frontiers in Allergy, 2021, 2, 780425.	1.2	5
38	Prophages encoding human immune evasion cluster genes are enriched in Staphylococcus aureus isolated from chronic rhinosinusitis patients with nasal polyps. Microbial Genomics, 2021, 7, .	1.0	11
39	Barrier disruptive effects of mucus isolated from chronic rhinosinusitis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 200-203.	2.7	11
40	Inhibition of Staphylococcus aureus and Pseudomonas aeruginosa biofilms by quatsomes in low concentrations. Experimental Biology and Medicine, 2020, 245, 34-41.	1.1	15
41	The Microbiome of the Nasolacrimal System and Its Role in Nasolacrimal Duct Obstruction. Ophthalmic Plastic and Reconstructive Surgery, 2020, 36, 80-85.	0.4	7
42	Association between viral infection and increased mucosal eosinophils and CD8⁺CD103⁺ T cells in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2020, 10, 978-980.	1.5	0
43	Staphylococcus aureusbiofilm exoproteins are cytotoxic to human nasal epithelial barrier in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2020, 10, 871-883.	1.5	18
44	The international sinonasal microbiome study: A multicentre, multinational characterization of sinonasal bacterial ecology. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2037-2049.	2.7	55
45	Prevention of peridural adhesions in spinal surgery: Assessing safety and efficacy of Chitogel with Deferiprone in a sheep model. Journal of Clinical Neuroscience, 2020, 72, 378-385.	0.8	6
46	Antibiotics Affect ROS Production and Fibroblast Migration in an In-vitro Model of Sinonasal Wound Healing. Frontiers in Cellular and Infection Microbiology, 2020, 10, 110.	1.8	16
47	In vitro safety evaluation of a povidoneâ€iodine solution applied to human nasal epithelial cells. International Forum of Allergy and Rhinology, 2020, 10, 1141-1148.	1.5	26
48	Microbiotyping the Sinonasal Microbiome. Frontiers in Cellular and Infection Microbiology, 2020, 10, 137.	1.8	21
49	A Novel Rat Model to Test Intra-Abdominal Anti-adhesive Therapy. Frontiers in Surgery, 2020, 7, 12.	0.6	6
50	Spontaneous Regression of Swollen Submandibular Glands in IgG4-Related Disease. Allergy and Rhinology, 2019, 10, 215265671881673.	0.7	1
51	The effect of neutrophil serine proteases on human nasal epithelial cell barrier function. International Forum of Allergy and Rhinology, 2019, 9, 1220-1226.	1.5	29
52	Extent of maxillary sinus surgery and its effect on instrument access, irrigation penetration, and disease clearance. International Forum of Allergy and Rhinology, 2019, 9, 1097-1104.	1.5	15
53	Sub-Inhibitory Clindamycin and Azithromycin reduce S. aureus Exoprotein Induced Toxicity, Inflammation, Barrier Disruption and Invasion. Journal of Clinical Medicine, 2019, 8, 1617.	1.0	18
54	Manuka honey sinus irrigations in recalcitrant chronic rhinosinusitis: phase 1 randomized, singleâ€blinded, placeboâ€controlled trial. International Forum of Allergy and Rhinology, 2019, 9, 1470-1477.	1.5	20

#	Article	IF	Citations
55	Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due toStaphylococcus aureus. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 723.	1.2	105
56	Kappaâ€carrageenan sinus rinses reduce inflammation and intracellular Staphylococcus aureus infection in airway epithelial cells. International Forum of Allergy and Rhinology, 2019, 9, 918-925.	1.5	6
57	Pseudomonas aeruginosa Exoprotein-Induced Barrier Disruption Correlates With Elastase Activity and Marks Chronic Rhinosinusitis Severity. Frontiers in Cellular and Infection Microbiology, 2019, 9, 38.	1.8	31
58	Inducing a Mucosal Barrierâ€“Sparing Inflammatory Response in Laboratoryâ€Grown Primary Human Nasal Epithelial Cells. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2019, 80, e69.	1.1	16
59	The presence of virus significantly associates with chronic rhinosinusitis disease severity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1569-1572.	2.7	20
60	Deferiprone has anti-inflammatory properties and reduces fibroblast migration in vitro. Scientific Reports, 2019, 9, 2378.	1.6	20
61	Effect of commercial nasal steroid preparation on bacterial growth. International Forum of Allergy and Rhinology, 2019, 9, 766-775.	1.5	8
62	Safety and efficacy of a bacteriophage cocktail in an in vivo model of Pseudomonas aeruginosa sinusitis. Translational Research, 2019, 206, 41-56.	2.2	27
63	In vitro characteristics of an airway barrierâ€disrupting factor secreted by Staphylococcus aureus. International Forum of Allergy and Rhinology, 2019, 9, 187-196.	1.5	11
64	Role of fungi in chronic rhinosinusitis through ITS sequencing. Laryngoscope, 2018, 128, 16-22.	1.1	47
65	Staphylococcus Aureus V8 protease disrupts the integrity of the airway epithelial barrier and impairs ILâ€6 production in vitro. Laryngoscope, 2018, 128, E8-E15.	1.1	47
66	Bacteriophage effectively kills multidrug resistant Staphylococcus aureus clinical isolates from chronic rhinosinusitis patients. International Forum of Allergy and Rhinology, 2018, 8, 406-414.	1.5	37
67	Tertiary lymphoid organs: AÂnovel target in patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2018, 142, 1673-1676.	1.5	8
68	Staphylococcus aureus from patients with chronic rhinosinusitis show minimal genetic association between polyp and non-polyp phenotypes. BMC Ear, Nose and Throat Disorders, 2018, 18, 16.	2.6	8
69	Comparative Viral Sampling in the Sinonasal Passages; Different Viruses at Different Sites. Frontiers in Cellular and Infection Microbiology, 2018, 8, 334.	1.8	10
70	Sirtuin-1 Controls Poly (I:C)â€“Dependent Matrix Metalloproteinase 9 Activation in Primary Human Nasal Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 500-510.	1.4	14
71	Mucosal zinc deficiency in chronic rhinosinusitis with nasal polyposis contributes to barrier disruption and decreases <scp>ZO</scp>â€1. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2095-2097.	2.7	20
72	Primary human nasal epithelial cells: a source of poly (I:C) LMW-induced IL-6 production. Scientific Reports, 2018, 8, 11325.	1.6	26

#	Article	IF	Citations
73	Staphylococcus aureus small colony variants: Prevalence in chronic rhinosinusitis and induction by antibiotics. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2403-2405.	2.7	4
74	Topical Colloidal Silver for the Treatment of Recalcitrant Chronic Rhinosinusitis. Frontiers in Microbiology, 2018, 9, 720.	1.5	20
75	Safety and Efficacy of Topical Chitogel- Deferiprone-Gallium Protoporphyrin in Sheep Model. Frontiers in Microbiology, 2018, 9, 917.	1.5	13
76	Naive and Effector B-cell Subtypes are Increased in Chronic Rhinosinusitis with Polyps. American Journal of Rhinology and Allergy, 2018, 32, 3-6.	1.0	11
77	Discordant frequencies of tissueâ€resident and circulating CD180â€negative B cells in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2017, 7, 609-614.	1.5	3
78	A Topical Hydrogel with Deferiprone and Gallium-Protoporphyrin Targets Bacterial Iron Metabolism and Has Antibiofilm Activity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	58
79	Taking the Silver Bullet Colloidal Silver Particles for the Topical Treatment of Biofilm-Related Infections. ACS Applied Materials & Interfaces, 2017, 9, 21631-21638.	4.0	43
80	Increased IL-13 expression is independently associated with neo-osteogenesis in patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2017, 140, 1444-1448.e11.	1.5	11
81	Nano-hemostats and a Pilot Study of Their Use in a Large Animal Model of Major Vessel Hemorrhage in Endoscopic Skull Base Surgery. Journal of Neurological Surgery, Part B: Skull Base, 2017, 38, 215-221.	0.4	0
82	In vitro safety evaluation of human nasal epithelial cell monolayers exposed to carrageenan sinus wash. International Forum of Allergy and Rhinology, 2017, 7, 1170-1177.	1.5	21
83	Tertiary lymphoid organs in recalcitrant chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1371-1373.e6.	1.5	21
84	Identification of the Bacterial Reservoirs for the Middle Ear Using Phylogenic Analysis. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 155.	1.2	24
85	Chronic Rhinosinusitis with Polyps Is Characterized by Increased Mucosal and Blood Th17 Effector Cytokine Producing Cells. Frontiers in Physiology, 2017, 8, 898.	1.3	18
86	Long-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Region. Frontiers in Cellular and Infection Microbiology, 2017, 7, 49.	1.8	44
87	Deferiprone and Gallium-Protoporphyrin Have the Capacity to Potentiate the Activity of Antibiotics in Staphylococcus aureus Small Colony Variants. Frontiers in Cellular and Infection Microbiology, 2017, 7, 280.	1.8	47
88	Alloiococcus otitidis Forms Multispecies Biofilm with Haemophilus influenzae: Effects on Antibiotic Susceptibility and Growth in Adverse Conditions. Frontiers in Cellular and Infection Microbiology, 2017, 7, 344.	1.8	20
89	Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Frontiers in Cellular and Infection Microbiology, 2017, 7, 418.	1.8	132
90	Th17 Cytokines Disrupt the Airway Mucosal Barrier in Chronic Rhinosinusitis. Mediators of Inflammation, 2016, 2016, 1-7.	1.4	69

#	Article	IF	Citations
91	Reduced Innate Immune Response to a Staphylococcus aureus Small Colony Variant Compared to Its Wild-Type Parent Strain. Frontiers in Cellular and Infection Microbiology, 2016, 6, 187.	1.8	26
92	Innate lymphoid type 2 cells in chronic rhinosinusitis. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 7-12.	1.1	5
93	The Bacterial Microbiome in Chronic Rhinosinusitis: Richness, Diversity, Postoperative Changes, and Patient Outcomes. American Journal of Rhinology and Allergy, 2016, 30, 37-43.	1.0	66
94	Association of intracellular Staphylococcus aureus with prognosis in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2016, 6, 792-799.	1.5	24
95	The microbiome of otitis media with effusion. Laryngoscope, 2016, 126, 2844-2851.	1.1	62
96	Fighting sinusâ€derived Staphylococcus aureus biofilms in vitro with a bacteriophageâ€derived muralytic enzyme. International Forum of Allergy and Rhinology, 2016, 6, 349-355.	1.5	22
97	Subepithelial inflammatory load and basement membrane thickening in refractory chronic rhinosinusitis with nasal polyposis: a histopathological study. International Forum of Allergy and Rhinology, 2016, 6, 248-255.	1.5	30
98	Mind â€œDe GaPPâ€• in vitro efficacy of deferiprone and galliumâ€protoporphyrin against Staphylococcus aureus biofilms. International Forum of Allergy and Rhinology, 2016, 6, 737-743.	1.5	39
99	T regulatory and Th17 cells in chronic rhinosinusitis with polyps. International Forum of Allergy and Rhinology, 2016, 6, 826-834.	1.5	25
100	TLR response pathways in NuLi-1 cells and primary human nasal epithelial cells. Molecular Immunology, 2015, 68, 476-483.	1.0	19
101	Staphylococcus aureus impairs the airway epithelial barrier in vitro. International Forum of Allergy and Rhinology, 2015, 5, 551-556.	1.5	64
102	Staphylococcus Aureus Biofilms Induce Apoptosis and Expression of Interferon-Î³, Interleukin-10, and Interleukin-17A on Human Sinonasal Explants. American Journal of Rhinology and Allergy, 2015, 29, 23-28.	1.0	17
103	Role of crushed skeletal muscle extract in hemostasis. International Forum of Allergy and Rhinology, 2015, 5, 431-434.	1.5	4
104	Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm. PLoS ONE, 2015, 10, e0131806.	1.1	55
105	Quatsomes for the treatment of Staphylococcus aureus biofilm. Journal of Materials Chemistry B, 2015, 3, 2770-2777.	2.9	28
106	Topical colloidal silver as an antiâ€biofilm agent in a Staphylococcus aureus chronic rhinosinusitis sheep model. International Forum of Allergy and Rhinology, 2015, 5, 283-288.	1.5	21
107	An inÂvivo safety and efficacy demonstration of a topical liposomal nitric oxide donor treatment for Staphylococcus aureus biofilmâ€“associated rhinosinusitis. Translational Research, 2015, 166, 683-692.	2.2	29
108	Sinonasal Microbiome Sampling: A Comparison of Techniques. PLoS ONE, 2015, 10, e0123216.	1.1	60

#	Article	IF	Citations
109	Safety evaluation of a sinus surfactant in an explant-based cytotoxicity assay. Laryngoscope, 2014, 124, 369-372.	1.1	7
110	Early and late complications of endoscopic hemostatic techniques following different carotid artery injury characteristics. International Forum of Allergy and Rhinology, 2014, 4, 651-657.	1.5	36
111	Smallâ€colony variants and phenotype switching of intracellular <scp>S</scp>taphylococcus aureus in chronic rhinosinusitis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1364-1371.	2.7	38
112	Corticosteroids directly reduce Staphylococcus aureus biofilm growth: An in vitro study. Laryngoscope, 2014, 124, 602-607.	1.1	24
113	Colloidal silver: a novel treatment for Staphylococcus aureus biofilms?. International Forum of Allergy and Rhinology, 2014, 4, 171-175.	1.5	26
114	Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis. International Forum of Allergy and Rhinology, 2014, 4, 176-186.	1.5	50
115	Methylglyoxalâ€augmented manuka honey as a topical antiâ€“Staphylococcus aureus biofilm agent: safety and efficacy in an in vivo model. International Forum of Allergy and Rhinology, 2014, 4, 187-195.	1.5	56
116	The fungal microbiome in chronic rhinosinusitis: richness, diversity, postoperative changes and patient outcomes. International Forum of Allergy and Rhinology, 2014, 4, 259-265.	1.5	76
117	Probiotic manipulation of the chronic rhinosinusitis microbiome. International Forum of Allergy and Rhinology, 2014, 4, 309-314.	1.5	60
118	Association between Group 2 Innate Lymphoid Cells enrichment, nasal polyps and allergy in Chronic Rhinosinusitis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1154-1161.	2.7	151
119	Bacteriophage Reduces Biofilm of Staphylococcus Aureus Ex Vivo Isolates from Chronic Rhinosinusitis Patients. American Journal of Rhinology and Allergy, 2014, 28, 3-11.	1.0	55
120	Cousins, siblings, or copies: the genomics of recurrent Staphylococcus aureus infections in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2014, 4, 953-960.	1.5	26
121	Liposome-Encapsulated ISMN: A Novel Nitric Oxide-Based Therapeutic Agent against Staphylococcus aureus Biofilms. PLoS ONE, 2014, 9, e92117.	1.1	39
122	A human nasal explant model to study Staphylococcus aureus biofilm in vitro. International Forum of Allergy and Rhinology, 2013, 3, 556-562.	1.5	15
123	Gene expression differences in nitric oxide and reactive oxygen species regulation point to an altered innate immune response in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2013, 3, 193-198.	1.5	16
124	Staphylococcus aureus biofilm activates the nucleotideâ€binding oligomerization domain containing 2 (Nod2) pathway and proinflammatory factors on a human sinonasal explant model. International Forum of Allergy and Rhinology, 2013, 3, 877-884.	1.5	11
125	Intracellular Staphylococcus aureus: the Trojan horse of recalcitrant chronic rhinosinusitis?. International Forum of Allergy and Rhinology, 2013, 3, 261-266.	1.5	56
126	Identifying Intracellular Staphylococcus Aureus in Chronic Rhinosinusitis: A Direct Comparison of Techniques. American Journal of Rhinology and Allergy, 2012, 26, 444-449.	1.0	13

#	Article	IF	Citations
127	Prevention of false positive binding during immunofluorescence of Staphylococcus aureus infected tissue biopsies. Journal of Immunological Methods, 2012, 384, 111-117.	0.6	8
128	Nuclear Myosin VI Enhances RNA Polymerase II-Dependent Transcription. Molecular Cell, 2006, 23, 749-755.	4.5	123
129	SPPL2a and SPPL2b promote intramembrane proteolysis of TNFÎ± in activated dendritic cells to trigger IL-12 production. Nature Cell Biology, 2006, 8, 843-848.	4.6	175
130	From flies' eyes to our ears: Mutations in a human class III myosin cause progressive nonsyndromic hearing loss DFNB30. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7518-7523.	3.3	230
131	USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. European Journal of Human Genetics, 2002, 10, 339-350.	1.4	153
132	Beethoven, a mouse model for dominant, progressive hearing loss DFNA36. Nature Genetics, 2002, 30, 257-258.	9.4	246
133	High frequency of the deafness-associated 167delT mutation in the connexin 26 (GJB2) gene in Israeli Ashkenazim. American Journal of Medical Genetics Part A, 1999, 86, 499-500.	2.4	67